title: Primary hepatic burkitt lymphoma presenting with acute liver failure.
abstract: BACKGROUND
  We report the first case of immunophenotypically confirmed primary hepatic Burkitt lymphoma presenting with acute liver failure. The patient survived following an aggressive diagnostic approach followed by emergent chemotherapy.
  
  
  CONCLUSIONS
  Data from the primary hepatic non-Hodgkin lymphoma literature show a survival rate of 87% at 5 years with combination regimens of chemotherapy. However, mortality rate in this population is 85% in patients with acute liver failure.
  
  
  CONCLUSIONS
  Primary hepatic Burkitt lymphoma may respond well to emergent chemotherapy even in the setting of acute liver failure.
authors.affiliation: Division of Gastroenterology and Hepatology, Washington Hospital Center, 110 Irving St NW, Rm no 3A-3, Washington, DC 20010, USA. wissam.e.mattar@medstar.net
authors.forename: Wissam E
authors.initials: WE
authors.lastname: Mattar
authors.forename: Biju K
authors.initials: BK
authors.lastname: Alex
authors.forename: Averell H
authors.initials: AH
authors.lastname: Sherker
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active; D002051:Burkitt Lymphoma / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D017114:Liver Failure, Acute / Q000209:etiology* / Q000503:physiopathology; D008113:Liver Neoplasms / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D003561:Cytarabine; D000069283:Rituximab; D003907:Dexamethasone
references.citation: Eur J Gastroenterol Hepatol. 1997 Nov;9(11):1113-5
references.pmid: 9431904
references.citation: Int J Infect Dis. 2000;4(1):57-8
references.pmid: 10689218
references.citation: Int J Cancer. 2009 Apr 15;124(8):1745-55
references.pmid: 19165855
references.citation: Cancer. 2001 Oct 15;92(8):2023-9
references.pmid: 11596015
references.citation: Korean J Gastroenterol. 2008 Apr;51(4):259-64
references.pmid: 18516006
references.citation: Lancet Oncol. 2003 Jan;4(1):22-9
references.pmid: 12517536
references.citation: Hepatology. 1991 May;13(5):870-5
references.pmid: 2029991
references.citation: Acta Haematol. 2001;105(4):237-40
references.pmid: 11528098
references.citation: Blood. 2004 Nov 15;104(10):3009-20
references.pmid: 15265787
references.citation: Am J Gastroenterol. 2003 Jul;98(7):1641-6
references.pmid: 12873593
references.citation: Gut. 1998 Apr;42(4):576-80
references.pmid: 9616324
references.citation: Leuk Lymphoma. 2001 Feb;40(5-6):667-70
references.pmid: 11426539
references.citation: Clin Radiol. 2006 May;61(5):453-5
references.pmid: 16679121